GT200900284A - Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.- - Google Patents
Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.-Info
- Publication number
- GT200900284A GT200900284A GT200900284A GT200900284A GT200900284A GT 200900284 A GT200900284 A GT 200900284A GT 200900284 A GT200900284 A GT 200900284A GT 200900284 A GT200900284 A GT 200900284A GT 200900284 A GT200900284 A GT 200900284A
- Authority
- GT
- Guatemala
- Prior art keywords
- reversible
- direct
- intravenous
- inhibitor
- oral dose
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
EL INVENTO SE REFIERE A MÉTODOS Y COMPUESTOS PARA UNA INHIBICIÓN PLAQUETARIA RÁPIDA Y REVERSIBLE EN SUJETOS HUMANOS QUE NECESITAN DE LA MISMA. SON COMPUESTOS INHIBIDORES DE P2Y12 DE ACCIÓN DIRECTA, YA SEA SOLOS O EN COMBINACIÓN CON UN SEGUNDO AGENTE QUE PUEDE SER ASPIRINA O UN AGENTE TROMBOLÍTICO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91564907P | 2007-05-02 | 2007-05-02 | |
US94792107P | 2007-07-03 | 2007-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200900284A true GT200900284A (es) | 2012-01-31 |
Family
ID=39587015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200900284A GT200900284A (es) | 2007-05-02 | 2009-10-30 | Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.- |
Country Status (17)
Country | Link |
---|---|
US (2) | US20090048216A1 (es) |
EP (1) | EP2079464A2 (es) |
JP (1) | JP2010526101A (es) |
KR (1) | KR20100029746A (es) |
CN (1) | CN101795682A (es) |
AU (1) | AU2008247483A1 (es) |
BR (1) | BRPI0811476A2 (es) |
CA (1) | CA2686203A1 (es) |
CO (1) | CO6241104A2 (es) |
EA (1) | EA200901473A1 (es) |
EC (1) | ECSP099778A (es) |
GT (1) | GT200900284A (es) |
IL (1) | IL201834A0 (es) |
MA (1) | MA31663B1 (es) |
MX (1) | MX2009011843A (es) |
TN (1) | TN2009000451A1 (es) |
WO (1) | WO2008137753A2 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ567747A (en) * | 2005-11-03 | 2011-11-25 | Portola Pharm Inc | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
MX2009009492A (es) * | 2007-03-06 | 2009-09-15 | Novartis Ag | Compuestos organicos biciclicos adecuados para el tratamiento de condiciones inflamatorias o alergicas. |
CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
JP5851246B2 (ja) * | 2008-12-30 | 2016-02-03 | リグスホスピタルRigshospitalet | 臓器不全の発生リスクが上昇した重篤患者を識別する方法およびその治療のための化合物 |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
CA2778880C (en) | 2009-11-11 | 2018-02-13 | The Medicines Company | Methods of treating or preventing stent thrombosis |
ES2548845T3 (es) * | 2009-12-23 | 2015-10-21 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor y ácido acetilsalicílico |
US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
EP2646827A1 (en) * | 2010-12-01 | 2013-10-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
US8987285B2 (en) * | 2010-12-03 | 2015-03-24 | Portola Pharmaceuticals, Inc. | Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof |
AU2018234056B2 (en) | 2017-03-15 | 2023-05-25 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a P2Y12 receptor antagonist |
BR112019022676A2 (pt) | 2017-06-23 | 2020-05-19 | Chiesi Farm Spa | método de prevenção de trombose de derivação da artéria sistêmica-para-pulmonar |
CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
NZ567747A (en) | 2005-11-03 | 2011-11-25 | Portola Pharm Inc | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
-
2008
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Application Discontinuation
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en active Application Filing
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2686203A1 (en) | 2008-11-13 |
MA31663B1 (fr) | 2010-09-01 |
ECSP099778A (es) | 2010-01-29 |
US20090048216A1 (en) | 2009-02-19 |
JP2010526101A (ja) | 2010-07-29 |
EA200901473A1 (ru) | 2010-06-30 |
IL201834A0 (en) | 2010-06-16 |
WO2008137753A3 (en) | 2009-02-12 |
CO6241104A2 (es) | 2011-01-20 |
US20120009172A1 (en) | 2012-01-12 |
MX2009011843A (es) | 2010-04-22 |
CN101795682A (zh) | 2010-08-04 |
BRPI0811476A2 (pt) | 2014-11-04 |
TN2009000451A1 (en) | 2011-03-31 |
EP2079464A2 (en) | 2009-07-22 |
WO2008137753A2 (en) | 2008-11-13 |
KR20100029746A (ko) | 2010-03-17 |
AU2008247483A1 (en) | 2008-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200900284A (es) | Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.- | |
AR068185A1 (es) | Composiciones de tabletas de desintegracion oral de lamotrigina | |
CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
HK1160779A1 (en) | Cdk inhibitor for the treatment of mesothelioma | |
BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
PA8850801A1 (es) | Compuestos útiles para inhibir chk1 | |
AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
CL2010001361A1 (es) | Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension. | |
CO6351725A2 (es) | Derivados de picolinamida como inhibidores de quinasa | |
DOP2012000290A (es) | 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario | |
GT200900008A (es) | Derivados novedosos de aminopiridina que tienen acción inhibidora selectiva sobre aurora a | |
ECSP088218A (es) | Bencimidazoles sustituidos como inhibidores de cinasa | |
SV2010003673A (es) | Compuestos heterociclicos novedosos y usos de los mismos | |
CL2009000625A1 (es) | Composicion farmaceutica que comprende a)un primer poliol seleccionado de manitol, sorbitol o una combinacion de ambos, b)segundo poliol seleccionado de propilenglicol, glicerina o una combinacion de ambas, c)complejo de borato en un 0,5% p/v de la composicion total, d)preservante, e)agua; util para el tratamiento del ojo. | |
HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
CR11418A (es) | Trans-clomifeno para el sindrome metabolico | |
CL2012000333A1 (es) | Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico. | |
CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
AR083395A1 (es) | Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico | |
CL2011000806A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
CL2008000610A1 (es) | Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor. | |
AR056500A1 (es) | Metodo para preparar una composicion medica | |
PA8784901A1 (es) | Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. |